BRAF V600E等位基因频率与甲状腺乳头状癌临床病理结局的关联
该回顾性队列研究纳入2016至2019年UCLA Health连续73例Bethesda V/VI结节且孤立BRAF V600E突变、术后病理为甲状腺乳头状癌的患者,中位等位基因频率25.5%。较高等位基因频率与肉眼甲状腺外侵犯、肿瘤≥2 cm及疾病持续/复发相关,等位基因频率≥35%与更差的无复发生存相关(HR 7.40;CI 1.4-38.1)。
要点
- 中位BRAF V600E等位基因频率为25.5%(IQR 16.7%-34.3%)。
- 肉眼甲状腺外侵犯者等位基因频率40.1% vs 无肉眼侵犯者25.2%(P = .02)。
- 等位基因频率≥35%与更差无复发生存相关(HR 7.40;CI 1.4-38.1)。
核心结论
- 较高的BRAF V600E等位基因频率与肉眼甲状腺外侵犯和复发风险增加相关,可能有助于指导携带孤立BRAF V600E突变甲状腺乳头状癌患者的初始管理。
研究设计与样本
- 2016至2019年在UCLA Health开展的回顾性队列研究,纳入连续73例Bethesda V/VI结节且孤立BRAF V600E突变、接受手术且组织病理学显示甲状腺乳头状癌的患者,初始管理和随访完成后进行盲法ThyroSeq v3分子分析。
主要发现
- 73例患者中位BRAF V600E等位基因频率为25.5%(IQR 16.7%-34.3%)。
- 美国甲状腺协会高风险组中位等位基因频率37% vs 中风险组25.3%(P < .01)vs 低风险组24.7%(P < .01)。
- 有肉眼甲状腺外侵犯者等位基因频率40.1% vs 无肉眼侵犯者25.2%(P = .02)。
- 肿瘤≥2 cm者等位基因频率中位32.0% vs <2 cm者24.4%(P < .01)。
- 中位随访4.1年,7例(9.4%)出现疾病持续/复发,复发者中位等位基因频率35.3% vs 无复发者25.2%(P = .02);等位基因频率≥35%与更差无复发生存相关(HR 7.40;CI 1.4-38.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: BRAF V600E mutation is the most common genetic driver of papillary thyroid cancer (PTC), where it is found with various allele frequency (AF), reflecting the proportion of cells carrying the mutant and wild-type gene alleles. OBJECTIVE: To determine whether BRAF V600E AF can improve prognostication and inform initial surgical management of PTC. METHODS: This retrospective cohort study (2016-2019) at UCLA Health included consecutive patients with Bethesda V/VI nodules and isolated BRAF V600E mutation who underwent surgery with histopathology showing PTC. Blinded ThyroSeq v3 molecular analysis was conducted after completion of initial management and follow-up. The risk of aggressive histopathology and cancer persistence/recurrence were assessed. RESULTS: Of 73 patients, the median BRAF V600E AF was 25.5% (IQR, 16.7%-34.3%). Higher median AF was seen in patients classified as American Thyroid Association high-risk (37%) vs intermediate-risk (25.3%, P < .01) and low-risk (24.7%, P < .01), largely attributed to higher AF in patients with gross extrathyroidal extension (ETE) (40.1% vs 25.2% without gross ETE, P = .02). No differences in AF were observed on the basis of lymph node positivity or presence of aggressive variants of PTC. A higher BRAF V600E AF was also found in patients with tumors ≥ 2 cm vs < 2 cm (median 32.0% vs 24.4%, P < .01). Over 4.1 years of follow-up, disease persistence/recurrence was found in 7 patients (9.4%) and was associated with higher median AF than those without recurrence (35.3% vs 25.2%, P = .02). Higher AF was associated with poorer recurrence-free survival (AF ≥ 35%; HR 7.40; CI, 1.4-38.1). CONCLUSION: Higher AF was associated with gross ETE and increased recurrence risk. This may inform initial management in patients with PTC harboring an isolated BRAF V600E mutation.
引用
- Schumm MA, Nikiforov YE, Nikiforova MN, et al. Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39541427. doi:10.1210/clinem/dgae774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。